Article info
PDFCommentary
Natalizumab and PML: a risky business?
- Professor David B Clifford, Seay Professor of Neuropharmacology in Neurology, Department of Neurology, Box 8111, 660 South Euclid Avenue, Saint Louis, MO 63110, USA; cliffordd{at}neuro.wustl.edu
Citation
Natalizumab and PML: a risky business?
Publication history
- First published September 12, 2008.
Online issue publication
April 18, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2008 BMJ Publishing Group and British Society of Gastroenterology